Zevra Therapeutics (ZVRA) experienced a significant drop of 9.44%, traded at $10.65 in after-hours trading, despite reporting strong Q2 financial results.
The decline after-hours is puzzling as ZVRA’s Q2 earnings of $1.24 per share and revenue of $25.9 million exceeded analysts’ expectations, significantly improving from last year’s losses.
The stock ended the regular session at $11.76, after fluctuating between $11.75 and $12.05 throughout the day on a volume of 1.71 million shares.
